OncoImmunity Becomes the First Company to Obtain the CE-IVD Mark for Clinical Use of a Machine-Learning Based Neoantigen Prediction Technology
OncoImmunity has become the first company to obtain a CE-IVD mark for the clinical use of a machine-learning based neoantigen prediction technology. This quality assurance certification represents an important step in raising the standards for the use of neoantigen prediction technologies for the design of personalized cancer vaccines and cell therapies.
The certification means that personalized cancer vaccine and cell therapy companies can now meet their own quality assurance requirements for their clinical development by leveraging OncoImmunity’s proven quality assurance methodology. OncoImmunity’s neoantigen prediction technology, known as the Immuneoprofiler™, allows cancer immunotherapy companies to gain access to a quality assured prediction technology that also has superior performance in predicting the presentation of neoantigens to the tumor cell surface.
Richard Stratford CEO at OncoImmunity said:
“At OncoImmunity we understand intimately the complexity of neoantigen prediction and the need to select neoantigens for personalized cancer immunotherapy to a high clinical standard. We have designed machine-learning solutions to fill some of the gaps in the neoantigen prediction challenge and this certification of the Immuneoprofiler™ will facilitate both cost-saving and time-efficient filing for the accreditation of our partners cancer immunotherapy platforms”
The CE-mark (CE-IVD) indicates that an IVD device complies with the European In Vitro Diagnostics Directive (98/79/EC), and that the device may be legally commercialized and distributed in the EU.
OncoImmunity is a machine-learning company offering a proprietary technology to address the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy. OncoImmunity's software facilitates effective patient selection for cancer immunotherapy and identifies neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable time-frame.
Trevor Clancy Ph.D.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
CA-VELODYNE-LIDAR,-INC.19.3.2019 02:02:07 CET | Pressemeddelelse
Velodyne Demonstrates Lidar Solution for Rich Perception Data Collection on NVIDIA DRIVE Platform
WESTERN-UNION19.3.2019 02:02:07 CET | Pressemeddelelse
Western Union Teams Up with Thunes to Expand Payout Capabilities to Mobile Wallets
WI-KOHLER-CO.19.3.2019 01:24:05 CET | Pressemeddelelse
Kohler Celebrates the Details of Design at Milan Design Week 2019
AMS19.3.2019 01:11:14 CET | Pressemeddelelse
ams and Wise Road Capital Advance Further Development for Environmental, Flow and Pressure Sensors Through Creation of a Joint Venture
NY-WEWORK-COMPANIES19.3.2019 00:46:12 CET | Pressemeddelelse
The We Company FY 2018 Financial Results Conference Call
NV-RIMINI-STREET19.3.2019 00:02:10 CET | Pressemeddelelse
FANCL Regains Control of Their IT Roadmap by Switching to Rimini Street Support for its SAP Application
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum